摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴-3-甲氧基吡啶盐酸盐 | 109911-38-8

中文名称
4-溴-3-甲氧基吡啶盐酸盐
中文别名
4-溴-3-甲氧基吡啶
英文名称
4-bromo-3-methoxypyridine
英文别名
——
4-溴-3-甲氧基吡啶盐酸盐化学式
CAS
109911-38-8
化学式
C6H6BrNO
mdl
——
分子量
188.024
InChiKey
RLJLJPJHDXLJFY-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    230℃
  • 密度:
    1.530
  • 闪点:
    93℃

计算性质

  • 辛醇/水分配系数(LogP):
    1.5
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    22.1
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

SDS

SDS:3b20939341e04745e6a5a625e70dcbe1
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 4-Bromo-3-methoxypyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 4-Bromo-3-methoxypyridine
CAS number: 109911-38-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H6BrNO
Molecular weight: 188.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

反应信息

  • 作为反应物:
    描述:
    4-溴-3-甲氧基吡啶盐酸盐 在 nickel dichloride 、 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 48.0h, 以32%的产率得到3,3'-Dimethoxy-4,4'-bipyridin
    参考文献:
    名称:
    Dehmlow, Eckehard V.; Sleegers, Arthur, Liebigs Annalen der Chemie, 1992, # 9, p. 953 - 960
    摘要:
    DOI:
  • 作为产物:
    描述:
    参考文献:
    名称:
    [EN] PEST CONTROL AGENT
    [FR] AGENT DE LUTTE CONTRE LES ORGANISMES NUISIBLES
    摘要:
    本发明的目的是提供一种对害虫高度活性的化合物,提供包括该化合物的杀虫剂,并提供一种通过应用该化合物来控制害虫的方法。本发明提供了一种4-(芳基乙炔基)吡啶或其盐,一种包括4-(芳基乙炔基)吡啶或其盐作为活性成分的杀虫剂,以及一种通过应用4-(芳基乙炔基)吡啶或其盐的有效量来控制害虫的方法。
    公开号:
    WO2014098259A1
点击查看最新优质反应信息

文献信息

  • [EN] CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2<br/>[FR] ANTAGONISTES DU CCR2 À BASE DE CYCLOHEXYL-AZÉTIDINYLE
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:WO2011159854A1
    公开(公告)日:2011-12-22
    The present invention comprises compounds of Formula (I). Wherein: R1, R2, R4, J, Q, and A are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).
    本发明包括公式(I)的化合物。其中:R1、R2、R4、J、Q和A如说明书所述定义。本发明还包括预防、治疗或改善综合征、障碍或疾病的方法,其中所述综合征、障碍或疾病为2型糖尿病、肥胖和哮喘。本发明还包括通过管理治疗有效量的至少一种公式(I)化合物来抑制哺乳动物中的CCR2活性的方法。
  • BENZIMIDAZOLE CANNABINOID AGONISTS BEARING A SUBSTITUTED HETEROCYCLIC GROUP
    申请人:JANSSEN PHARMACEUTICA NV
    公开号:US20130324529A1
    公开(公告)日:2013-12-05
    The present invention is related to novel benzimidazole compounds of formula (I) having cannabinoid receptor agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals, in particular humans.
    本发明涉及具有大麻素受体激动性质的新型苯并咪唑化合物(I)的公式,包括这些化合物的药物组合物,制备这些化合物的化学过程以及它们在治疗与大麻素受体在动物中介导相关的疾病,特别是人类中的用途。
  • ORGANIC COMPOUND, ELECTROCHROMIC COMPOUND, AND ELECTROCHROMIC ELEMENT, OPTICAL FILTER, LENS UNIT, IMAGING DEVICE, AND WINDOW COMPONENT HAVING SAME
    申请人:CANON KABUSHIKI KAISHA
    公开号:US20170329195A1
    公开(公告)日:2017-11-16
    An organic compound represented by General Formula (1), in which, in General Formula (1), R 1 represents an alkyl group or an alkoxy group, X 1 and X 2 are each independently selected from an alkyl group which may have a substituent, an aryl group which may have a substituent, or an aralkyl group which may have a substituent, and A 1 − and A 2 − each independently represent a monovalent anion.
    在通用公式(1)中,R1代表一个烷基或烷氧基,X1和X2各自独立地从可能含有一个取代基的烷基、可能含有一个取代基的芳基或可能含有一个取代基的芳烷基中选择,A1-和A2-各自独立地代表一个单价阴离子。
  • [EN] SHP2 INHIBITORS<br/>[FR] INHIBITEURS DE SHP2
    申请人:IRBM S P A
    公开号:WO2021028362A1
    公开(公告)日:2021-02-18
    The present invention relates to new compounds capable of inhibiting the activity of SHP2 phosphatase, having the general Formula (I).
    本发明涉及一种能够抑制SHP2磷酸酶活性的新化合物,其具有一般式(I)。
  • Identification of novel GLUT inhibitors
    作者:Holger Siebeneicher、Marcus Bauser、Bernd Buchmann、Iring Heisler、Thomas Müller、Roland Neuhaus、Hartmut Rehwinkel、Joachim Telser、Ludwig Zorn
    DOI:10.1016/j.bmcl.2016.02.050
    日期:2016.4
    The compound class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS as very potent inhibitors of facilitated glucose transporter 1 (GLUT1). Extensive structure–activity relationship studies (SAR) of each ring system of the molecular framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine). The selectivity against
    使用HTS将1 H-吡唑并[3,4- d ]嘧啶类化合物鉴定为促进葡萄糖转运蛋白1(GLUT1)的非常有效的抑制剂。建立了分子框架每个环系统的广泛结构-活性关系研究(SAR),揭示了必要的结构动机(即,邻甲氧基取代的苯,哌嗪和嘧啶)。对GLUT2的选择性非常好,并且最初的体外和体内药代动力学(PK)研究令人鼓舞。
查看更多